ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% – Time to Sell?

ADC Therapeutics SA (NYSE:ADCT)’s share price traded down 4.5% during trading on Thursday . The company traded as low as $3.88 and last traded at $3.9050. 740,786 shares traded hands during mid-day trading, an increase of 12% from the average session volume of 659,677 shares. The stock had previously closed at $4.09.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $5.00 price target on shares of ADC Therapeutics in a research note on Wednesday, December 3rd. Guggenheim reiterated a “buy” rating and set a $10.00 target price on shares of ADC Therapeutics in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, January 21st. HC Wainwright dropped their price target on ADC Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, October 16th. Finally, Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

ADC Therapeutics Price Performance

The firm has a market capitalization of $483.74 million, a price-to-earnings ratio of -2.69 and a beta of 1.93. The business’s 50 day moving average price is $3.73 and its 200-day moving average price is $3.67.

ADC Therapeutics (NYSE:ADCT) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.10. The business had revenue of $16.43 million during the quarter, compared to analysts’ expectations of $17.08 million. As a group, analysts expect that ADC Therapeutics SA will post -1.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. R Squared Ltd purchased a new stake in shares of ADC Therapeutics during the 3rd quarter worth $59,000. Henrickson Nauta Wealth Advisors Inc. acquired a new stake in shares of ADC Therapeutics in the fourth quarter valued at about $69,000. SG Americas Securities LLC acquired a new stake in shares of ADC Therapeutics in the fourth quarter valued at about $86,000. Creative Planning purchased a new stake in ADC Therapeutics during the second quarter worth about $96,000. Finally, Ethic Inc. acquired a new position in ADC Therapeutics during the second quarter worth about $103,000. Hedge funds and other institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.